How to appeal a Blue Cross Blue Shield of Michigan cystic fibrosis & pulmonary fibrosis denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

Blue Cross Blue Shield of Michigan-specific note: Largest insurer in Michigan (~4.5M members). Statutory non-profit mutual. Switched PBM from Express Scripts to OptumRx effective January 2024 — appeals around 2024-2025 may involve formulary disruption. Michigan DIFS oversight.

What Blue Cross Blue Shield of Michigan's policy requires for cystic fibrosis & pulmonary fibrosis

Cited policy: Anthem BCBS Clinical Guideline clinical guideline (CFTR Modulators)

Step therapy through older modulator typical.

How Blue Cross Blue Shield of Michigan denies cystic fibrosis & pulmonary fibrosis — and how to counter it

Where Blue Cross Blue Shield of Michigan pushes back: 1) Step therapy through Symdeko/Orkambi first; 2) Pediatric Trikafta denied age 3; 3) Mutation not on label.

Counter-arguments that hold up: Cite CFF 2023 first-line Trikafta recommendation; medical exception for genotype with superior Trikafta data. April 2023 FDA expansion to age 2-5 (VX20-445-111). CFTR2 database + CFF Modulator Eligibility tool for non-F508del responsive.

What Blue Cross Blue Shield of Michigan typically denies for cystic fibrosis & pulmonary fibrosis

Across Blue Cross Blue Shield of Michigan's commercial and Medicare books, denials cluster around a small number of patterns. For cystic fibrosis & pulmonary fibrosis, expect:

• Step therapy via OptumRx (PBM since 2024)
• Site-of-care reductions for infusions
• Behavioral health prior auth
• OON balance bill disputes

Treatments most often denied in this category

These are the cystic fibrosis & pulmonary fibrosis treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Trikafta
• Symdeko
• Orkambi
• Kalydeco
• Pulmozyme
• Hypertonic saline

How to submit the appeal to Blue Cross Blue Shield of Michigan

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Blue Cross Blue Shield of Michigan cited in the denial.
3. File the appeal through Blue Cross Blue Shield of Michigan's portal (members: https://www.bcbsm.com ; providers: https://providers.bcbsm.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In MI, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Blue Cross Blue Shield of Michigan's prior-authorization criteria by drug: Blue Cross Blue Shield of Michigan PA criteria on ApprovalHelp.